New Research Evidencing the Role of CBD to Inhibit the Establishment of Drug Reward With Morphine
LAS VEGAS, NV–(Marketwired – August 23, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), today cited additional research suggesting cannabidiol (CBD) may be efficacious in preventing and treating drug addictions.
A recent study conducted by researchers at the University of Mississippi and Elsohly Laboratories titled, “Effects of Cannabidiol on Morphine Conditioned Place Preference in Mice” demonstrated that in a murine model of drug addiction, the administration of CBD at a dose of 10mg/kg was effective in blocking behavior rewarded with opioids (morphine). The current study shows that CBD inhibits the establishment of a drug reward from morphine in mice, and therefore could play a role in making drugs like prescription opioids, for example, less addictive. Furthermore, prior research in animal models of psychostimulant addiction has demonstrated that CBD can reduce the risk of addiction relapse after achieving abstinence.
“The results of this study support the incorporation of CBD into treatment of addiction and reinforce the company’s position to further develop pharmaceutical-grade CBD as an adjunct to nicotine replacement therapy (NRT) for the treatment of smokeless tobacco addiction,” commented Amy McCord, Ph.D., Director of Drug Development for CV Sciences.
CV Sciences is pioneering the development of a unique formulation of synthetic CBD for the treatment of smokeless tobacco addiction. Research supporting the role of CBD in reducing the strength of an addiction and in inhibiting relapse after abstinence has important implications for the company’s use of CBD as an adjunct to nicotine replacement therapy in smokeless tobacco addiction. We believe that CBD use with NRT will have two important benefits: a meaningful, greater success rate of achieving abstinence from smokeless tobacco, and a reduced dependence on nicotine replacement therapy to maintain abstinence.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.